We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Receives FDA Warning Letter on GMP Violations
Merck Receives FDA Warning Letter on GMP Violations
August 5, 2005
The FDA has issued a warning letter to Merck charging the firm with a number of current good manufacturing practice violations in relation to its production of asparaginase intermediate, the main active ingredient in the firm’s cancer drug, Elspar.